Oculus Innovative Sciences (OCLS) Announces Development of a Microcyn Hydrogel Formulation
More News related to OCLS
- Oculus Innovative Sciences to Present at Canaccord Adams 28th Annual Global Growth Conference
- Oculus Innovative Sciences Reports 59% Increase in First Quarter Product Revenue
- Oculus Innovative Sciences Announces Fiscal First Quarter Financial Results and Corporate Update Release and Conference Call
- Oculus Innovative Sciences' CEO and Founder Named One of Pharmaceutical Executive's 2008 "Emerging Pharma Leaders"
- Oculus Innovative Sciences (OCLS) Announces Positive Results from Abstract Evaluating the Use of Microcyn(R) Technology in Treatment of Atopic Dermatitis
More News related to FDA
- Mylan (MYL) Subsidiary, Alphapharm, Wins Patent Challenge on First-to-fFile Opportunity Razadyne(R) Tablets
- Amylin (AMLN) Gets A Friend After Yesterday's 25% Sell-Off
- Barr Labs (BRL) Receives Final FDA Approval for Generic Version of Razadyne(R) Tablets
- Pro-Pharmaceuticals (PRW) Receives FDA IND Application for Use of DAVANAT(R)
- Valeant Pharmaceuticals (VRX) and GlaxoSmithKline Enter Collaboration for Retigabine
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced that the company's research and development team has completed work on the development of a Microcyn hydrogel formulation. Microcyn-Gel has been specifically designed to address a broad spectrum of applications including potential treatment of various skin disorders (acne, psoriasis, and dermatitis), as well as for use in wound care, cosmeceuticals, animal health care, treatment of burns and as an anti-fungal in foot care.
"We plan to file with the FDA," explained Hoji Alimi, Oculus founder and CEO, "our U.S. application for clearance of our hydrogel formulation as a 510k, or medical device. Once we have this clearance, we intend to distribute product immediately to the many hospitals and doctors across the United States that have been using the original 510k-cleared Microcyn solution with great success in the treatment of various wounds including diabetic foot ulcers, pressure ulcers, infected wounds, burns and more. Microcyn-Gel is further evidence of our commitment to the growth of our product portfolio based upon the Microcyn Technology."[SM]
Related Categories
FDAStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
